Spotlight On... Pfizer joins next-gen vaccines R&D consortium; AstraZeneca buys Orexo program; Genenta partners on gene therapy; and more...

Pfizer ($PFE) has joined the public/private Human Vaccines Project, which is engaged in the hunt for a new generation of vaccines that can tackle cancer, HIV, dengue and more. "Over the last decade, we've seen unprecedented technological advances in our understanding of the biology of diseases, and new tools in designing vaccines including therapeutic vaccines. Yet the translation from preclinical to clinical vaccine research has often been hampered by a lack of understanding of the desired human immune responses required to obtain optimal vaccine protection," said Kathrin Jansen, senior vice president and head of Vaccines Research & Development at Pfizer. Release

@FierceBiotech: Duchenne docs--AKA Sarepta investigators, advisers and advocates--back controversial case for eteplirsen. Article | Follow @FierceBiotech

@JohnCFierce: J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies. News | Follow @JohnCFierce

> AstraZeneca ($AZN) is buying all of Orexo's leukotriene C4 synthase inhibitor program (OX-CLI project) for MUSD 5. Release

> Italy's Genenta Science will collaborate with MolMed on a new gene therapy for multiple myeloma. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Theranos gets the boot as host for Clinton campaign fundraiser. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Med tech consultant discusses China FDA, tries to clear up Chinese clinical trial confusion. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Embark Veterinary launches DNA testing kit for dogs with research applications in mind. FierceAnimalHealth story | Follow @EmilyWFierce

> 23andMe broadens R&D footprint with new genetic service through Apple's ResearchKit. Story

> San Diego's Acutus grabs $75M to get 3-D, real-time surgical cardiac imaging past regulators. More

> Endeavour Vision closes $275M dedicated med tech, digital health fund. Article

Pharma News

@FiercePharma: Humor or fear? Merck uses both to promote shingles shot Zostavax. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Switching study gives Celltrion biosim more ammo in fight for Remicade share. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Novartis CEO Jimenez sees pay drop to $11.9M on Alcon, emerging markets shortfalls. Story

> Could a Bausch & Lomb IPO help save debt-laden Valeant? Ackman thinks so. More

> Amgen's PCSK9 patent win 'reasonably likely' to push Sanofi's Praluent off the market: Analyst. Report

> Anthem sues Express Scripts over drug pricing, considers calling it quits on the PBM. Article

Drug Delivery News

> S. Korean diabetes patch monitors blood sugar and delivers metformin. More

> GSK partnering with Germany's Miltenyi Biotec on cell and gene therapy R&D. Report

> Halozyme initiates Phase III trial of its internal pancreatic cancer candidate. Story

> 'Backpacks' on white blood cells could deliver cancer drugs in a targeted fashion. Article

> Inovio acquires needle-free jet injector tech from Bioject for $5.5M. News

Pharma Manufacturing News

> WHO suspends manufacturing approval of Indian TB drug maker Svizera. Report

> Hitachi Chemical and PCT ink deal for licensing, manufacturing for cell therapy. News

> Boehringer Ingelheim wins first client for China biologics plan. Story

> China hunts for $88M in vaccines diverted to black market. Item

> Marksans the latest Indian drugmaker cited with noncompliance by European regulators. Article

Pharma Asia News

> India's Svizera Labs suspended as TB drugs supplier to WHO. News

> Diabetes in focus as Lechleiter's Asian tour reaches China. Article

> CANbridge in potential $134M licensing deal with AVEO Oncology drug. Story

> Cancer care triage in Asia shows treatment options gap. More

> China FDA on the hunt for illegally sold vaccines in Shandong. Report

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.